520 Newport Center Drive
Suite 1200
Newport Beach, CA 92660
United States
(949) 284-4555
https://www.evolus.com
Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 279
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. David Moatazedi | President, CEO & Director | 1.75M | N/A | 1978 |
Ms. Sandra Beaver | Chief Financial Officer | 740.15k | N/A | 1978 |
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research & Development | 823.19k | N/A | 1962 |
Mr. Nareg Sagherian | Head of Global Investor Relations & Corporate Communications | N/A | N/A | N/A |
Mr. Jeffrey J. Plumer | General Counsel | N/A | N/A | N/A |
Mr. Kurt Knab | Vice President of Sales | N/A | N/A | N/A |
Ms. Tomoko Yamagishi-Dressler | Chief Marketing Officer | N/A | N/A | N/A |
Ms. Jessica Novak | Senior Vice President of Human Resources | N/A | N/A | N/A |
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 9.